Inhibikase Therapeutics, Inc. (IKT) is a publicly traded company in the Unknown sector. Across all available filings, 8 corporate insiders have executed 22 transactions totaling $3.1M, demonstrating a bullish sentiment with $3.1M in net insider flow. The most recent transaction on Feb 21, 2026 involved a transaction of 19,089 shares valued at $0.
No significant insider buying has been recorded for IKT in the recent period.
No significant insider selling has been recorded for IKT in the recent period.
Based on recent SEC filings, insider sentiment for IKT is bullish with an Insider Alignment Score of 100/100 and a net flow of $3.1M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Inhibikase Therapeutics, Inc. (IKT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 8 insiders are actively trading IKT stock, having executed 22 transactions in the past 90 days. The most active insider is Frank M. Sands (Executive), who has made 1 transactions totaling $3.0M.
Get notified when executives and directors at IKT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 21, 2026 | Munshi Amit | Executive | Disposition | 19,089 | $N/A | $0 | |
| Feb 21, 2026 | Cabell Christopher | President & Head of R&D | Disposition | 338,282 | $N/A | $0 | |
| Feb 21, 2026 | Aurentz Vincent | Executive | Disposition | 255,299 | $N/A | $0 | |
| Jan 5, 2026 | Mcintyre David | Chief Financial Officer | Award | 986,319 | $N/A | $0 | C-Suite |
| Jan 5, 2026 | Cabell Christopher | President & Head of R&D | Award | 900,117 | $N/A | $0 | |
| Jan 5, 2026 | T. Iwicki Mark | Executive | Award | 4,982,706 | $N/A | $0 | |
| Nov 21, 2025 | M. Sands Frank | Executive | Purchase | 2,068,965 | $1.45 | $3.0M | Large |
| Feb 21, 2025 | Munshi Amit | Executive | Award | 57,265 | $N/A | $0 | |
| Aug 16, 2022 | H. Werner Milton | Executive | Purchase | 5,000 | $0.80 | $4.0K | |
| May 27, 2022 | H. Werner Milton | Executive | Purchase | 5,000 | $0.98 | $4.9K | |
| May 20, 2022 | H. Werner Milton | Executive | Purchase | 10,000 | $0.60 | $6.0K | |
| May 19, 2022 | Frattaroli Joseph | Executive | Purchase | 3,948 | $0.64 | $2.5K | |
| Jan 3, 2022 | H. Werner Milton | Executive | Option Exercise | 21,853 | $2.02 | $44.1K | |
| Nov 17, 2021 | H. Werner Milton | Executive | Purchase | 1,100 | $1.97 | $2.2K | |
| Nov 17, 2021 | H. Werner Milton | Executive | Purchase | 17,569 | $1.98 | $34.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 10 | $3.1M | 83.1% |
Conversion(C) | 1 | $441.4K | 12.0% |
Exercise(M) | 3 | $104.9K | 2.8% |
Payment(F) | 1 | $77.7K | 2.1% |
Disposition(D) | 3 | $0 | 0.0% |
Award(A) | 4 | $0 | 0.0% |
Insiders at Inhibikase Therapeutics, Inc. are accumulating shares at an accelerated pace. With 8 insiders making 22 transactions totaling $3.1M in purchases versus $0 in sales, the net buying activity of $3.1M signals strong executive confidence. Frank M. Sands (Executive) leads the buying activity with $3.0M in transactions across all time.